Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX Study - Bordeaux Population Health Accéder directement au contenu
Article Dans Une Revue Pharmaceutics Année : 2021

Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX Study

Thibaud Mathis
Jad Akesbi
  • Fonction : Auteur
Nicolas Voirin
  • Fonction : Auteur
Frederic Matonti
  • Fonction : Auteur
Franck Fajnkuchen
  • Fonction : Auteur
John Conrath
  • Fonction : Auteur
Solange Milazzo
  • Fonction : Auteur
Stephanie Baillif
Philippe Denis
  • Fonction : Auteur
Catherine Creuzot-Garcher
Mayer Srour
  • Fonction : Auteur
Benedicte Dupas
  • Fonction : Auteur
Aditya Sudhalkar
  • Fonction : Auteur
Alper Bilgic
  • Fonction : Auteur
Ramin Tadayoni
  • Fonction : Auteur
Eric H. Souied
  • Fonction : Auteur
Corinne Dot
  • Fonction : Auteur

Résumé

The purpose of this study is to evaluate the visual acuity (VA) gain profiles between patients with drug-naive diabetic macular edema (DME) treated by dexamethasone implant (DEX-implant) and assess the baseline anatomical and functional factors that could influence the response to the treatment in real-life conditions. A retrospective, multi-center observational study included 129 eyes with drug-naive DME treated by DEX-implant. The Median follow-up was 13 months. Two groups of VA gain trajectories were identified-Group A, with 71% (n = 96) of patients whose average VA gain was less than five letters and Group B, with 29% (n = 33) of patients with an average gain of 20 letters. The probability of belonging to Group B was significantly higher in patients with baseline VA \textbackslashtextless 37 letters (p = 0.001). Ellipsoid zone alterations (EZAs) or disorganization of retinal inner layers (DRILs) were associated with a lower final VA (53.0 letters versus 66.4, p = 0.002) but without a significant difference in VA gain (4.9 letters versus 6.8, p = 0.582). Despite a low baseline VA, this subgroup of patients tends to have greater visual gain, encouraging treatment with DEX-implant in such advanced-stage disease. However, some baseline anatomic parameters, such as the presence of EZAs or DRILs, negatively influenced final vision.
Fichier principal
Vignette du fichier
BPH_Pharmaceutics_2021_Pinto.pdf (7.75 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03190826 , version 1 (06-04-2021)

Identifiants

Citer

Mauricio Pinto, Thibaud Mathis, Pascale Massin, Jad Akesbi, Theo Lereuil, et al.. Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX Study. Pharmaceutics, 2021, 13 (2), pp.194. ⟨10.3390/pharmaceutics13020194⟩. ⟨hal-03190826⟩

Collections

HCL U1219
43 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More